Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats

Nanotoxicology

Volumn 8, Issue SUPPL. 1, 2014, Pages 128-137

  Li, Dingsheng ^a   Johanson, Gunnar ^b   Emond, Claude ^c   Carlander, Ulrika ^b   Philbert, Martin ^a   Jolliet, Olivier ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BioSimulation Consulting Inc   (United States)

Author keywords

Nanoparticles; Phagocytosis; Physiologically based pharmacokinetic modeling biodistribution

Indexed keywords

MACROGOL; NANOPARTICLE; POLYACRYLAMIDE; ACRYLIC ACID RESIN; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CAPILLARY BLOOD; CAPILLARY PERMEABILITY; CONTROLLED STUDY; HEALTH HAZARD; HEART; KIDNEY; LIVER; LUNG; MATHEMATICAL MODEL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE DISTRIBUTION; TOXICOKINETICS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; PHARMACOKINETICS;

ACRYLIC RESINS; ANIMALS; MODELS, BIOLOGICAL; NANOPARTICLES; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; RATS; TISSUE DISTRIBUTION;

EID: 84905980836     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.863406     Document Type: Article

References (53)

1. Abbott LC, Maynard AD. 2010. Exposure assessment approaches for engineered nanomaterials. Risk Anal 30: 1634-44.
2. Alpini G, Phillips JO, Vroman B, Larusso NF. 1994. Recent advances in the isolation of liver-cells. Hepatology 20: 494-514.
3. Bernareggi A, Rowland M. 1991. Physiologic modeling of cyclosporine kinetics in rat and man. J Pharmacokinet Biopharm 19: 21-50.
4. Brookes M. 1967. Blood flow rates in compact and cancellous bone and bone marrow. J Anat 101: 533-41.
5. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407-84.
6. Cassee FR, van Balen EC, Singh C, Green D, Muijser H, Weinstein J, Dreher K. 2011. Exposure, health and ecological effects review of engineered nanoscale cerium and cerium oxide associated with its use as a fuel additive. Crit Rev Toxicol 41: 213-29.
7. Chithrani BD, Chan WC. 2007. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 7: 1542-50.
8. Chithrani BD, Ghazani AA, Chan WCW. 2006. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 6: 662-8.
9. Cho M, Cho WS, Choi M, Kim SJ, Han BS, Kim SH, et al. 2009. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett 189: 177-83.
10. Demoy M, Andreux JP, Weingarten C, Gouritin B, Guilloux V, Couvreur P. 1999. Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharm Res 16: 37-41.
11. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, et al. 2006. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Persp 114: 1172-8.
12. Hardas SS, Butterfield DA, Sultana R, Tseng MT, Dan M, Florence RL, et al. 2010. Brain distribution and toxicological evaluation of a systemically delivered engineered nanoscale ceria. Toxicol Sci 116: 562-76.
13. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. 2007. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13: 636-41.
14. Keighron JD, Ewing AG, Cans AS. 2012. Analytical tools to monitor exocytosis: a focus on new fluorescent probes and methods. Analyst 137: 1755-63.
15. Khlebtsov N, Dykman L. 2011. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 40: 1647-71.
16. Krishnan K. 2007. Physiologically based pharmacokinetic and toxicokinetic models. In: Hayes AW, ed. Principles and Methods of Toxicology. Boca Raton: CRC Press, 231-92.
17. Kuruppuarachchi M, Savoie H, Lowry A, Alonso C, Boyle RW. 2011. Polyacrylamide nanoparticles as a delivery system in photodynamic therapy. Mol Pharmaceut 8: 920-31.
18. Lang CH, Dobrescu C. 1991. Sepsis-induced increase in glucose-uptake by macrophage-rich tissues persist during hypoglycemia. Metabolism 40: 585-93.
19. Lankveld DPK, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, et al. 2010. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 31: 8350-61.
20. Lee HA, Leavens TL, Mason SE, Monteiro-Riviere NA, Riviere JE. 2009. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. Nano Lett 9: 794-9.
21. 2 and silver. Inhal Toxicol 23: 226-36.
22. Li M, Al-Jamal KT, Kostarelos K, Reineke J. 2010. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4: 6303-17.
23. Li M,Panagi Z, Avgoustakis K, Reineke J. 2012. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomed 7: 1345-56.
24. Lin P, Chen JW, Chang LW, Wu JP, Redding L, Chang H, et al. 2008. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. Environ Sci Technol 42: 6264-70.
25. Liu MX, Li HF, Luo G, Liu QF, Wang YM. 2008. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch Pharm Res 31: 547-54.
26. Luciani N, Gazeau F, Wilhelm C. 2009. Reactivity of the monocyte/macrophage system to superparamagnetic anionic nanoparticles. J Mater Chem 19: 6373-80.
27. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. 2008. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 105: 14265-70.
28. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 41: 315-21.
29. McKone TE. 1993. The precision of QSAR methods for estimating intermedia transfer factors in exposure assessments. SAR QSAR Environ Res 1: 41-51.
30. Moghimi SM. 2002. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biophys Biochem Acta Mol Cell Res 1590: 131-9.
31. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 53: 283-318.
32. Nel AE, Maedler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, et al. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8: 543-57.
33. Nemmar A, Hoet PHM, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, et al. 2002. Passage of inhaled particles into the blood circulation in humans. Circulation 105: 411-14.
34. Oberdörster G, Oberdörster E, Oberdörster J. 2005. Nanotoxicology: an emerging discipline evolving from studies of ultrafineparticles. Environ Health Persp 113: 823-39.
35. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, KreylingW, et al. 2004. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16: 437-45.
36. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Lunts A, et al. 2002. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A 65: 1531-43.
37. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. 2001. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharmaceut 221: 143-52.
38. Robert D, Pamme N, Conjeaud H, Gazeau F, Iles A, Wilhelm C. 2011. Cell sorting by endocytotic capacity in a microfluidic magnetophoresis device. Lab Chip 11: 1902-10.
39. Sadauskas E, Wallin H, Stoltenberg M, Vogel U, Doering P, Larsen A, et al. 2007. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 4: 10.
40. Sayes CM, Wahi R, Kurian PA, Liu YP, West JL, Ausman KD, et al. 2006. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol Sci 92: 174-85.
41. Semmler M, Seitz J, Erbe F, Mayer P, Heyder J, Oberdorster G, et al. 2004. Long-term clearance kinetics of inhaled ultrafine insoluble iridium particles from the rat lung, including transient translocation into secondary organs. Inhal Toxicol 16: 453-9.
42. Smith EA, Prues SL, Oehme FW. 1996. Environmental degradation of polyacrylamides. 1. Effects of artificial environmental conditions: temperature, light, and pH. Ecotox Environ Safe 35: 121-35.
43. Smith EA, Prues SL, Oehme FW. 1997. Environmental degradation of polyacrylamides. 2. Effects of environmental (outdoor) exposure. Ecotox Environ Safe 37: 76-91.
44. Teorell T. 1937. Kinetics of distribution of substances administered to the body I The extravascular modes of administration. Arch Int Pharmacodyn Ther 57: 205-25.
45. Travlos GS. 2006. Normal structure, function, and histology of the bone marrow. Toxicol Pathol 34: 548-65.
46. Walkey CD, Olsen JB, Guo HB, Emili A, Chan WCW. 2012. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 134: 2139-47.
47. 2 particles: differential responses related to surface properties. Toxicology 230: 90-104.
48. Weinberg H, Galyean A, Leopold M. 2011. Evaluating engineered nanoparticles in natural waters. Trend Anal Chem 30: 72-83.
49. Wenger Y, Schneider RJ, Reddy GR, Kopelman R, Jolliet O, Philbert MA. 2011. Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. Toxicol Appl Pharm 251: 181-90.
50. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. 2003. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 24: 1001-11.
51. Wilhelm C, Gazeau F, Roger J, Pons JN, Bacri JC. 2002. Interaction of anionic superparamagnetic nanoparticles with cells: kinetic analyses of membrane adsorption and subsequent internalization. Langmuir 18: 8148-55.
52. Yokel RA, Au TC, Macphail R, Hardas SS, Butterfield DA, Sultana R, et al. 2012. Distribution, elimination, and biopersistence to 90 Days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. Toxicol Sci 127: 256-68.
53. 2 exhibits adverse effects at environmental relevant concentrations. Environ Sci Technol 45: 3725-30.